Medical device marketing agency: the FDA words that decide every claim, and how to judge an agency before it writes one

A medical device marketing agency plans and produces marketing for companies that make and sell devices, from surgical tools to diagnostic tests and home monitors. The good ones differ from general healthcare agencies in one way: every claim they write has to match what the device was cleared or approved to do. In the US that is set by FDA rules on intended use, misbranding and premarket review. So the first test of an agency is not its creative work. It is whether its writers know why "FDA cleared" and "FDA approved" are different phrases, and why neither can appear before the device has reached market.

This guide covers what the work includes, the US rules that shape it, and how to judge an agency before you sign. Device companies selling outside the US face their own regulator and advertising code in each market, so a global launch needs a review step for each one.

What a device marketing agency actually does

Device marketing has two buyers at once. A clinician decides whether the device is right for the patient. A hospital value analysis committee, a purchasing team or a distributor decides whether to buy it. Consumer devices add a third audience, the patient or carer. A device agency usually covers:

• Positioning and messaging built from the cleared or approved indication, with a claims matrix that links each claim to its source.
• Clinical content: evidence summaries, product pages, procedure videos and training material for sales reps.
• Launch and trade show work: booth material, product launch campaigns and congress presence.
• Digital channels: search, LinkedIn and email aimed at clinicians and buyers, plus consumer channels where the device is sold direct.
• Market access content: economic value material for purchasing committees.

A general picture of how healthcare agencies split by client type, including where device work sits, is in our guide to health care marketing agencies and the review chain.

The US rules every device claim runs into

These come from the Code of Federal Regulations (Title 21, read 21 October 2026) and the Federal Food, Drug, and Cosmetic Act. Your regulatory team owns the final call. An agency should know them well enough to stop a bad claim before it reaches review.

Cleared is not approved

Most devices reach the US market through a premarket notification, usually called a 510(k). FDA's rule at 21 CFR 807.97 says that a finding of substantial equivalence "does not in any way denote official approval of the device". It goes further: any representation that creates an impression of official approval because of the 510(k) "is misleading and constitutes misbranding". So a 510(k) device is "FDA cleared", never "FDA approved", and design choices such as an FDA style seal can create the same impression as the words.

Devices that go through premarket approval (PMA) are approved, but the approval order sets conditions. Under 21 CFR 814.80, a device may not be labeled, distributed or advertised in a way that is inconsistent with any condition of its PMA approval order. Ask to see the approval conditions before any campaign is planned.

Intended use is shown by your advertising

21 CFR 801.4 defines intended use as the objective intent of the company responsible for the labeling. That intent can be shown by labeling claims, advertising matter, or oral or written statements by the company or its representatives. In plain terms, an ad, a webinar slide or a rep's talking point can create a new intended use. That is why claims beyond the cleared or approved indication, often called off label claims, are a regulatory issue and not only a style issue.

The same rule gives a useful boundary: a company is not treated as intending an unapproved use solely because it knows healthcare providers use the device that way. Knowledge is not promotion. Promotion is.

No promotion before clearance or approval

For a device still in a clinical study, 21 CFR 812.7 says a sponsor, or anyone acting for the sponsor, may not promote or test market an investigational device until FDA has approved it for commercial distribution, and may not represent that it is safe or effective for the purposes under investigation. "Coming soon" campaigns, pre-launch landing pages and congress material need careful wording for this reason. Clinical trial recruitment ads are a separate category again: Google's Healthcare and medicines policy (read 21 October 2026) does not allow them in most locations, and where it does, they may not imply the product being tested is safe.

Comparisons and restricted devices

Under 21 CFR 801.6, a false or misleading statement in labeling about another device, drug, food or cosmetic makes your device misbranded. Comparison claims against a competitor need the same evidence standard as any other claim.

Who regulates the advertising depends on the device. Section 502(q) and (r) of the Act (21 U.S.C. 352) give FDA authority over advertising for restricted devices, including a requirement that ads carry a brief statement of intended uses and relevant warnings, precautions, side effects and contraindications. For other devices, the FTC Act's ban on false advertising for "food, drugs, devices, services, or cosmetics" (15 U.S.C. 52) applies. Your agency should ask which category your device is in before writing a single ad.

Social media and misinformation

FDA issued draft guidance in June 2014 on presenting risk and benefit information on platforms with character limits. In July 2024 it published a revised draft, "Addressing Misinformation About Medical Devices and Prescription Drugs: Questions and Answers" (Federal Register 2024-15009), which replaces its 2014 draft on correcting third party misinformation. Both are drafts. An agency running your social accounts should have a written plan for responding to misleading posts about your device that follows the current draft.

Phrase or practice	The rule behind it	Safer approach
"FDA approved" on a 510(k) device	21 CFR 807.97	"FDA cleared" with the cleared indication
A use outside the indication in an ad or rep deck	21 CFR 801.4	Claims matrix tied to the indication
Pre-launch promotion of a device in a study	21 CFR 812.7	Corporate news only, reviewed by regulatory
Ad that steps outside PMA conditions	21 CFR 814.80	Brief the agency on the approval order
Unsupported "better than" claims	21 CFR 801.6	Head to head data or no comparison

How to judge a medical device marketing agency

Agencies that list devices as a specialty range from large health networks to small medtech shops. Size matters less than how claims are handled. Ask these questions in the first meeting:

• Show us your claims process. A good answer includes a claims matrix, reference tagging on every claim and a named step for your regulatory, legal and medical review.
• Which device classes have you marketed? A Class II 510(k) product and a Class III PMA product carry different constraints.
• Who writes clinical content? Look for writers with clinical or scientific backgrounds who can read a clinical study, not just summarise a press release.
• How do you handle reps' material? Sales training and leave behinds are where off label language most often slips in.
• How do you work across markets? If you sell outside the US, ask how they review claims against each market's rules.
• How do you measure? Device sales cycles are long. Expect pipeline measures such as qualified clinician enquiries, demo requests and evaluations, not only clicks.

Red flags include an agency that treats regulatory review as a delay, promises growth figures before seeing your evidence, or proposes patient testimonials without a plan for checking that each one stays within the indication.

Medical device marketing agency questions

What is the difference between FDA cleared and FDA approved?

Cleared means FDA found the device substantially equivalent to a legally marketed device through a 510(k). Approved means it passed premarket approval. FDA's own rule says 510(k) clearance does not denote official approval, so the two words are not interchangeable.

Can a device company market an off label use?

Advertising and statements by the company or its reps can establish a new intended use under 21 CFR 801.4. Keep promotion to the cleared or approved indication, and route any scientific exchange about other uses through your medical and regulatory teams.

Can we promote a device before it is cleared?

Not if it is an investigational device in a study. 21 CFR 812.7 bars promotion or test marketing until FDA authorises commercial distribution. Plan launch campaigns so they go live on the day authorisation is confirmed.

Does a device company need a specialist agency?

If claims review is your main risk, a specialist saves time because its writers already work inside the rules. A strong business to business agency can also work if your own regulatory team is closely involved from the first brief.

Who regulates medical device advertising in the US?

FDA regulates labeling for all devices and advertising for restricted devices. The FTC's false advertising rules apply to advertising for other devices.

When a clinician asks an assistant which device to consider

Clinicians, buyers and patients now ask assistants such as ChatGPT and Gemini questions like "what are the options for at home sleep apnea testing?" The answer names products and makers, and it can repeat a claim the maker never made, such as calling a cleared device approved. That is a regulatory problem as well as a marketing one. AI Knows Us is a new kind of measurement for this: it records which devices assistants name for a clinical question and what they say about each, so your team can see the answer a buyer sees and fix the public sources behind it.